Imricor Medical Systems (ASX:IMR) - Chair and CEO, Steve Wedan
Chair and CEO, Steve Wedan
Source: Imricor
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Imricor Medical Systems (IMR) announces enrolling two more customer sites in Berlin
  • The German Heart Centre Berlin and the Charité Medical University Virchow-Klinikum Campus are the latest institutions to adopt the company’s iCMR ablation solutions, bringing the total number Imricor sites to 13
  • Both institutions will use a lab at the German Heart Centre Berlin but will separately purchase the company’s catheters and other consumable products
  • The agreement has a term of three years with either party able to terminate it at any time
  • Shares have been trading 6.06 per cent higher today at $1.05 each

Imricor Medical Systems (IMR) has announced it has enrolled two more customer sites in Berlin.

The German Heart Centre Berlin and the Charité Medical University Virchow-Klinikum Campus are the latest institutions to adopt the company’s Interventional Cardiac Magnetic Resonance Imaging (iCMR) ablation solutions. This brings the total number of Imricor sites to 13.

The company specialises in MRI compatible products for cardiac ablation procedures. This is the process of inserting a thin, flexible tube called catheters into the veins or arteries which creates heat or cold energy to restore a normal heartbeat.

IMR signed an equipment purchase agreement with the German Heart Centre Berlin to outfit an existing CMR for iCMR procedures. Both institutions will then use the lab.

The institutions will both separately purchase Imricor’s catheters and other consumable devices.

The agreement has a term of three years and either party may terminate the agreement at any time.

Chair and CEO Steve Wedan said this is major step forward for the company.

“These sites have well-established facilities and programs like the MRI Core Lab and the CMR-Academy, and we look forward to growing and deepening our relationships and collaborations with them in the coming months and years.”

The company said this is a key strategic goal to grow the number of sites performing realtime iCMR cardiac ablation procedures in Europe. Planning is underway for procedures to commence in the first half of 2022.

Shares were trading 6.06 per cent higher today at $1.05 each at 12:35 pm AEDT.

IMR by the numbers
More From The Market Online
The Market Online Video

Market Close: ASX steams uphill but still on track to recovery

The ASX200 closed .4 of a per cent up with IT and Health Care the locomotives…
The Market Online Video

Market Update: ASX edges up with a healthier disposition

The ASX200 is trading up around half a per cent with Health Care and Real Estate…
Magnetite

Fe grades above 71% make Cyclone Metals bullish about Iron Bear pilot plant

Cyclone Metals, an iron ore developer which has built its business progressing Canadian magnetite play Iron…

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…